FTRE Stock Summary and Trading Ideas (Fortrea Holdings | NASDAQ:FTRE)

Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.

Fortrea Holdings trades on the NASDAQ stock market under the symbol FTRE.

As of April 15, 2025, FTRE stock price declined to $4.91 with 809,841 million shares trading.

FTRE has a beta of 1.70, meaning it tends to be more sensitive to market movements. FTRE has a correlation of 0.17 to the broad based SPY ETF.

FTRE has a market cap of $440.43 million. This is considered a Small Cap stock.

Last quarter Fortrea Holdings reported $697 million in Revenue and $.18 earnings per share. This fell short of revenue expectation by $-6 million and missed earnings estimates by -$.19.

The top ETF exchange traded funds that FTRE belongs to (by Net Assets): VTI, VB, IJR, VBR, VXF.

FTRE has underperformed the market in the last year with a price return of -87.4% while the SPY ETF gained +7.0%. FTRE has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -72.2% and -35.0%, respectively, while the SPY returned -7.1% and -3.6%, respectively.

FTRE support price is $5.05 and resistance is $5.67 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that FTRE shares will trade within this expected range on the day.